Novartis AG (CHIX:NOVNz)
CHF 88.07 0.11 (0.13%) Market Cap: 175.82 Bil Enterprise Value: 191.83 Bil PE Ratio: 11.84 PB Ratio: 4.79 GF Score: 60/100

Novartis AG at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 25, 2021 / 05:00PM GMT
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD & Senior Research Analyst

Hi, everyone. Welcome to our noon session today. My name is Daina Graybosch. I'm one of the senior analysts here at Leerink, and I'm really delighted to host Novartis, where we have Rob Kowalski who leads Regulatory Affairs and is the U.S. Head of Global Drug Development.

Thank you so much for joining us today.

Robert Kowalski
Novartis AG - Head of Global Regulatory Affairs

Thanks, Daina. Happy to be here with. Looking forward to the opportunity. Thank you.

Questions & Answers

Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD & Senior Research Analyst

We're going jump right into the questions, but first, some housekeeping. (Operator Instructions) Although, of course, I could spend probably 2 hours on my own questions.

So with that, let's jump right in. Impressively, Entresto has been one of Novartis's pretty key drugs, bringing in $2.5 billion in 2020 and growing 44%

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot